Report overview
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
This report aims to provide a comprehensive presentation of the global market for Solid Tumors Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Tumors Drugs. This report contains market size and forecasts of Solid Tumors Drugs in global, including the following market information:
Global Solid Tumors Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Solid Tumors Drugs Market Sales, 2018-2023, 2024-2030, (K Pcs)
Global top five Solid Tumors Drugs companies in 2022 (%)
The global Solid Tumors Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
We surveyed the Solid Tumors Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Solid Tumors Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, by Type, 2022 (%)
Small Molecules
Biologics
Global Solid Tumors Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Academic and Research Institutes
Others
Global Solid Tumors Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Solid Tumors Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Solid Tumors Drugs revenues share in global market, 2022 (%)
Key companies Solid Tumors Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Solid Tumors Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo
Outline of Major Chapters:
Chapter 1: Introduces the definition of Solid Tumors Drugs, market overview.
Chapter 2: Global Solid Tumors Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Solid Tumors Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Solid Tumors Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Solid Tumors Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
